NetraMark and Juvenescence extend collaboration

Partnership sees AI platform expanded into drug repurposing and discovery.

Canadian AI technology firm NetraMark yesterday announced the extension of its NetraPharma collaboration agreement with Longevity focused life sciences company Juvenescence. NetraPharma is described as a clinical-development focused machine learning initiative and is a 50/50 partnership between the companies.

The companies originally teamed up to use the AI platform for drug resurrection – extracting hidden information from failed or failing clinical trials – but have now expanded the scope of work to include drug repurposing and drug discovery. This announcement highlights a move from psychiatric indications to more focus on Longevity.

Drug repurposing, or indication expansion, is becoming a significant area of research and development, with existing products like aspirin, Metformin and Rapamycin all showing potential as therapies for Longevity related conditions.

Dr Greg Bailey, CEO of Juvenescence, said, “We see this as a novel collaboration to combine NetraMark’s diverse and unique machine learning platform with Juvenescence, as we are positioned as one of the leading drug development companies in the rapidly expanding sector focused on developing therapies to modify aging.”

NetraPharma uses a novel mathematical technique to integrate the outputs of multiple different machine learning algorithms, including gradient boosting, random forests, neural networks, GANs, quantum computation, and others. It enables the segmentation of subgroups within datasets when only a limited number of inputs are available. The system is claimed to be particularly adept at identifying placebo responders and non-responders, and with patient reported outcome measures (PROMs).

Dr Joseph Geraci, CEO of Toronto-based NetraMark, said, “After years of development and validation by the NetraMark tech team, the NetraAI machine learning suite is providing us with valuable insights into aging. The result is a very exciting collaboration with Juvenescence, one of the premier biotech companies focusing on modifying aging.”

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Latest articles

Exclusive interview: Professor Richard Faragher and cellular senescence

With senolytics driving investor interest in the Longevity sector, we speak to Professor Richard Faragher about resveratrol and the potential for rejuvenation of senescent...

Deep Longevity exits stealth to partner with HLI

Insilico announces Deep Longevity, a spin-out that will collaborate with Human Longevity Inc. to deploy an extensive range of AI-powered aging clocks. Insilico Medicine has...

Nanoparticles target immune response using red blood cells

Polystyrene nanoparticles deliver drug payload directly to the spleen and bypass lengthy clinical trial requirements. Vaccines are making headlines at the moment, for obvious reasons, ...

Alkahest reveals clinical trial progress

Alkahest pipeline sees multiple therapeutic candidates progressing through clinical trials. Biopharmaceutical company Alkahest has released details of its progress on a range of therapeutic candidates;...